PathAI Announces New Executive Appointment to Drive Commercial Growth of Biopharma Partnerships, Lab Capabilities, and Clinical Innovation

PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, announced that Matt Grow has joined as president of biopharma and chief business officer. The role will support PathAI’s expanding biopharma commercial organization with a focus on the company’s growing algorithm product suite and end-to-end clinical trial service offering for biopharma partners across all stages of drug development.

AiThority: The 3 Building Blocks to Make AI Accessible

With more than 20 years of experience in biopharma business development, Grow brings a wealth of expertise to PathAI. Prior to joining PathAI, he held key leadership roles at PPD and Thermo Fisher Scientific, where he served as senior vice president, global head of biopharma business development and was instrumental in driving growth and building strategic partnerships in the biopharmaceutical industry.

“We are thrilled to have Matt join the PathAI team as president of biopharma and chief business officer,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “His deep expertise in biopharma business development and commercial operations will be instrumental in driving growth and building strategic partnerships. We look forward to his leadership and contributions to the company’s success.”

Read More: How ChatGPT Will Transform Customer Service

As a strategic partner to the CEO and executive team, Grow will lead and manage the overall strategic direction and operations of PathAI’s BioPharma division, including business development, marketing and sales, and the BioPharma Lab operations.

“I have been supporting biopharma in this industry for over twenty years and I am energized by the PathAI end-to-end portfolio and how the technology is advancing drug development. I am thrilled to be joining such a strong team,” Grow said. “PathAI’s services and products are very impressive and address key pain points that customers face in clinical development by unlocking value, accuracy, and repeatability for late stage clinical trials and patients. As the portfolio continues to evolve, PathAI is strengthening its position to address the precise needs of each customer throughout the drug development spectrum. My goal is to ensure that we do this most effectively.”

Latest Insights: The Metaverse as the Great Diversity Experiment

[To share your insights with us, please write to sghosh@martechseries.com]